Welcome to our dedicated page for Clover Health Investments SEC filings (Ticker: CLOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating Medicare Advantage metrics, Star Ratings disclosures, or executive stock sales in Clover Health Investments Corp. (NASDAQ: CLOV) filings can feel like navigating a clinical trial protocol. Each 10-K spans hundreds of pages of risk-adjustment tables and value-based care jargon, and new 8-K announcements on CMS guidance appear without warning. Stock Titan solves that problem by pairing real-time EDGAR feeds with AI that translates dense language into plain English, so understanding Clover Health SEC documents with AI becomes routine.
Need the latest Clover Health quarterly earnings report 10-Q filing or curious about Clover Health insider trading Form 4 transactions? Our platform flags material changes—medical loss ratio shifts, membership growth, technology-licensing revenue—in seconds. AI-powered summaries underline where Clover Assistant costs are booked, while redlining highlights any section that affects revenue recognition. You can even set alerts for Clover Health Form 4 insider transactions real-time, keeping track of executive stock transactions Form 4 before the market digests them.
Use the dashboard to move from broad disclosure to actionable insight:
- Clover Health annual report 10-K simplified—spot Star Rating impacts, risk factors, and segment data
- Clover Health proxy statement executive compensation—compare incentive metrics tied to MA growth
- Clover Health 8-K material events explained—follow CMS rate notices or provider network changes
- Clover Health earnings report filing analysis—AI charts quarter-over-quarter medical cost trends
Whether you’re screening for Clover Health SEC filings explained simply or validating a thesis on value-based care adoption, Stock Titan delivers comprehensive coverage, expert context and the speed professional investors expect.
Anna U. Loengard, a director of Clover Health Investments, reported purchases of Class A common stock executed on 08/13/2025 and a reduction in previously reported beneficial ownership. The filing shows two custodial IRA purchases for the reporting person’s children: 12,000 shares at $2.60 and 14,500 shares at $2.59, held indirectly in a son’s and daughter’s IRA, respectively. The report also states the reporting person no longer has a reportable beneficial interest in 151,725 shares previously held by an ex-spouse. Following the transactions reported, Loengard beneficially owns 29,610 and 27,600 shares indirectly as noted.
Andrew Toy, who serves as both a Director and the Chief Executive Officer of Clover Health Investments (CLOV), reported that on 08/08/2025 85,535 shares of Class A common stock were automatically withheld to satisfy tax obligations when 6.25% of time-based restricted stock units (RSUs) granted on 08/08/2022 vested. The form reports a per-share price of $2.18 for the transaction. After the withholding, Mr. Toy directly beneficially owns 10,474,512 shares. The remaining RSUs continue to vest quarterly in equal 6.25% installments, with a final vesting date of 08/08/2026, subject to his continued service.
Clover Health Investments, Corp. published written responses to a selection of shareholder questions submitted before its second-quarter 2025 earnings announcement to increase engagement with its investor base. The company furnished those responses as Exhibit 99.1, and the Co‑Founder and Executive Chairman, Vivek Garipalli, provided separate written responses furnished as Exhibit 99.2. Both exhibits are furnished with the Current Report and are also available on the company’s investor relations website. The company states these materials are furnished for disclosure purposes and are not "filed" for Section 18 purposes and are not incorporated by reference into other filings except by specific reference.
Vivek Garipalli, a director and 10% owner of Clover Health Investments (CLOV), reported purchases of Class A common stock on 08/07/2025 and 08/08/2025. He acquired 415,000 shares on 08/07/2025 at a weighted average price of $2.24 and 31,980 shares on 08/08/2025 at a weighted average price of $2.17, bringing his reported direct ownership to 1,856,247 Class A shares.
Table II discloses substantial Class B common stock that converts one-for-one into Class A: 6,904,343 Class A-equivalent shares held directly, plus 11,500,000 and 72,084,543 Class A-equivalent shares held indirectly by Caesar Clover, LLC and NJ Healthcare Investments, LLC, respectively. The filing states Garipalli serves as sole manager of those LLCs.
Clover Health (CLOV) Q2 2025 10-Q snapshot
Premiums climbed 34% YoY to $469.8 m, lifting total revenue to $477.6 m, yet net medical claims surged 52% to $378.0 m, pushing the medical loss ratio to ~80.5% (71% in Q2 2024). Operating loss was $10.6 m versus prior-year profit of $7.2 m; GAAP EPS fell to –$0.02.
First-half revenue rose 34% to $939.9 m while net loss narrowed to $11.9 m (–$0.02 EPS) from $16.0 m, aided by a $2.8 m favourable prior-year claims development. Stock-based compensation remained high at $52.6 m YTD.
Cash & equivalents ended at $188.6 m, down $5.9 m YTD. Operating cash flow swung to a $10.9 m outflow (vs. $79.7 m inflow last year); investing inflows of $44.5 m offset $39.5 m used for equity-related financing. Total assets were $575 m and equity improved to $344 m.
Unpaid claims declined 11% YTD to $139.7 m; investment portfolio posted a $1.8 m unrealised gain, turning OCI positive. Weighted-average diluted shares stood at 509 m.
Management continues to expand Clover Assistant and Counterpart Health SaaS but flags medical cost inflation, RADV audit exposure and regulatory uncertainty as key risks.
FAQ
What is the current stock price of Clover Health Investments (CLOV)?
What is the market cap of Clover Health Investments (CLOV)?
